US 9,931,341 · Application 14/844,041 · Granted Apr 3, 2018
US 9,931,341
Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
Estimated expiration
December 12, 2032
6y 87d remaining
- Could not fetch continuity data for application PCTEP2012075294: Resource not found (404)
Earliest effective filing
Dec 12, 2012
+ 20 years
Dec 12, 2032
PTA +0d
Dec 12, 2032
No TD
—
Final
Dec 12, 2032
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.
Calculation details
Base term
- Filing date
- September 3, 2015
- Earliest effective filing
- December 12, 2012
- Issue date
- April 3, 2018
- PTA
- 0 days
- Base expiry (before PTA)
- December 12, 2032
December 12, 2012 + 20 years = December 12, 2032
- Continuation of application 14/364,320, filed Jun 11, 2014
- National stage entry of application PCTEP2012075294, filed Dec 12, 2012
- National stage entry of application PCTEP2012075294, filed Dec 12, 2012
Terminal disclaimers
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
The prosecution record for your AI
Application 14/844,041 · US 9,931,341
You have the date. Your AI can have the file.
PatentReply compiles the prosecution history behind US 9,931,341: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One public application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US9931341Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.